Sproutly Canada announced today that Infusion Biosciences and BNO Holdings have developed and verified analytical methods that detect, identify, and measure cannabinoid molecules in water-soluble (“Infuz2O”) and oil preparations (“Bio-Natural Oil”) derived from cannabis and hemp using APP Technology (collectively, the “Developed Analytics”). APP Technology is a patent-pending process that uses proprietary reagents to recover naturally occurring water-soluble cannabinoids as well as the cannabis oils.
"The proprietary methods for the Developed Analytics were created and refined during the past year through the work of Sproutly’s Chief Science Officer and Director Dr. Arup Sen in collaboration with state-certified US testing laboratories," the team with the company explains. "The delivery of the Developed Analytics satisfies Sproutly’s Earn Out Milestones (defined below) in the Acquisition Agreements (defined below) dated August 1, 2018 for the purchase of Infusion Biosciences Canada Inc. and SSM Partners."
The cannabis industry has faced challenges in testing and measuring cannabinoid content in water formulations fortified with cannabis ingredients. "Standard analytical methods used today for the detection and quantitation of cannabinoids had been designed for isolated oils and lack the ability to reliably measure cannabinoid contents in finished edible and beverage products," they further explain. "Correctly and reproducibly measuring the potency of bioactive cannabinoids in recreational, health and wellness, and medicinal beverage products is critical for successful marketing of these products in compliance with applicable food safety standards."
"Dr. Arup Sen and Infusion have been successful in developing a proprietary method for processing Infuz2O preparations in order to detect tetrahydrocannabinol (“THC”), cannabidiol (“CBD”) and several other cannabinoids. The proprietary process allows for independent third-party testing laboratories to prepare the cannabis and hemp samples of Infuz2O so that analytical methods used by these laboratories can then detect and measure the natural water-soluble cannabinoids. The results obtained in collaboration with third-party laboratories utilized for this research verify the predicted levels of cannabinoids recovered by APP Technology in Infuz2O."
Furthermore, lab result comparisons of cannabinoid profiles of the cannabis biomass before and after each step of APP Technology have revealed no detectable change in composition of the major cannabinoids and no indication of selective separation of cannabinoids from biomass in either Infuz2O or Bio-Natural Oil. Additional chemical tests carried out during this research further confirmed the molecular identity of cannabinoids in Infuz2O and Bio-Natural Oils to be the same as standard cannabinoid molecules.
Sproutly intends to provide technical guidance to qualified third-party testing laboratories in order to enable them to analyze Infuz2O products to meet applicable regulatory authority requirements for commercial sale of Sproutly’s products.
“The ability to test for cannabinoids in water formulations has been unreliable for cannabis beverages globally due to the existing testing standards and practices,” said Dr. Arup Sen, Chief Science Officer and Director of Sproutly. “With ever-increasing food-safety standards that need to be met for cannabis beverage and edible products, the completion of our research and the Developed Analytics are significant milestones in the commercialization of APP Technology; this is another step forward towards reliable and accurate testing for ingestible cannabis products.”
Further to its news release dated August 1, 2018, and in accordance with the acquisition agreements whereby the Company acquired all of the issued and outstanding shares of Infusion Biosciences Canada Inc. (a wholly owned subsidiary of Infusion Biosciences Inc.) and SSM Partners Inc. (together, the “AcquisitionAgreements“), the Earn Out Milestones (defined herein) were completed as of September 7, 2019 (the “Payment Date“). The earn-out milestones being the receipt of results for analysis of cannabinoids for water soluble and oil preparations derived with APP Technology, which results encompass analytical data that meet the regulatory requirements for the commercial sale of products in a Sproutly acquired jurisdiction (the “Earn Out Milestones”). In accordance with the provisions of the Acquisition Agreements Infusion Biosciences Inc. received 14,743,070 common shares and BNO Holdings (the former shareholder of SSM Partners Inc.) received 22,114,605 common shares of the Company (collectively, the “Earn Out Shares”). The Earn Out Shares are subject to the same escrow restrictions as the shares held by the Company management.